Corcept Therapeutics Stock Is Sliding on Hopes Delay

 Corcept Therapeutics’ shares are under pressure as investors reassess the risk and timing of returns from its early‑stage oncology pipeline. The company updated progress on two cancer trials — the TRIDENT study of relacorilant with frontline chemotherapy in metastatic pancreatic cancer, and a Phase 1b/2 trial of nenocorilant combined with the checkpoint inhibitor nivolumab — both of which are now recruiting patients. While analysts see potential for these combination therapies to meaningfully expand Corcept’s future market opportunity and support higher valuations if results are positive, the studies are single‑arm, early‑phase and will take years to deliver definitive data.

https://www.tipranks.com/news/catalyst/why-corcept-therapeutics-stock-is-sliding-on-hopes-delay